Reversal of oncogene transformation and suppression of tumor growth by the novel IGF1R kinase inhibitor A-928605
William N. Pappano(AbbVie (United States)), Jieyi Wang(Central South University), Fritz G. Buchanan(AbbVie (United States)), Randy L. Bell(University of Virginia), Steven K. Davidsen(Unknown), Paul Jung(Abbott (United States)), Cherrie K. Donawho(Abbott Fund), George S. Sheppard(AbbVie (United States)), M Grudzień(Abbott (United States)), Robert D. Hubbard(Abbott (United States)), Eric F. Johnson(Pfizer (United States)), Qian Zhang(Jiangsu Academy of Agricultural Sciences), Yichun Wang(Central South University), Jonathan A. Meulbroek(Abbott Fund), Niru B. Soni(AbbVie (United States))
Cited by 19
Related Papers
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
|Cancer Research|2008|2k
ABC transporters: the power to change
|Nature Reviews Molecular Cell Biology|2009|1.4k
Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours
|Nature|2017|878
ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models
|Clinical Cancer Research|2007|776